ViiV Healthcare Reports Results of Fostemsavir in P-III BRIGHTE Study for HIV-1 infection

 ViiV Healthcare Reports Results of Fostemsavir in P-III BRIGHTE Study for HIV-1 infection

ViiV Healthcare Initiates CUSTOMIZE Study of Dual- Drug Injectable Regimen for the Treatment of HIV

Shots:

  • The P-III BRIGHTE study involves assessing of fostemsavir + OBT vs PBO in 371 patients in a ratio (3:1) with HIV-1 infection who were resistant, intolerable and contraindicated to all ARV in at least four ARV classes
  • The P-III BRIGHTE study resulted in increased rates of virologic suppression and immunologic response from 48wks. to 96wks., @96wks. increase in CD4+ T-cell counts, 67% patients showed CD4 <200 cells/µL to a CD4 ≥200 cells/µL, 56% patients showed CD4 <50 cells/µL increased to a CD4 ≥200 cells/µL
  • Fostemsavir is a prodrug of temsavir that binds to the gp120 subunit within the HIV-1 envelope glycoprotein gp160 complex thus preventing the interaction between the virus and cellular CD4 receptors with its expected NDA submission in H2’19

Click here to read full press release/ article | Ref: GSK | Image: POZ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post